Lundbeck eyes major breakthrough for brain diseases

At pharmaceutical firm Lundbeck, EVP Keld Flintholm Jørgensen thinks quantam leaps are happening when it comes to brain diseases.

Photo: Thomas Borberg

Following a tumultuous time period involving a near-empty pipeline, multiple drug failures and a plummeting share price, the management of Lundbeck sees light at the end of the tunnel in its core area for central nervous system (CNS) diseases, which may have the potential to create a new era for the Danish pharmaceutical company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs